Paranovus Entertainment Technology (PAVS) Stock Analysis & Winston Score
Paranovus Entertainment Technology Ltd. is a small company based in China that has shifted its business focus over time, moving from entertainment and technology services toward pharmaceutical distribution. It sells pharmaceutical products and medical supplies, primarily serving customers in China's healthcare market. The company operates in a crowded and heavily regulated industry. Paranovus generates revenue mainly through product sales rather than subscriptions or licensing. It is a very small company, with a market cap that rounds to essentially zero, and it operates almost entirely within China. The company's gross margin of around 10% is thin for a pharmaceutical distributor, and its negative operating margin means it is currently spending more than it earns. The biggest risk the business faces is its lack of a clear competitive advantage — pharmaceutical distribution in China is highly fragmented, and small players without strong supplier relationships or scale often struggle to survive long-term.
Winston Score: 20/100 — Weak
Weak fundamentals across most pillars.
- Quality: Weak (1/30)
- Growth: Good (12/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Weak (1/15)
Key Facts
Price: $6.15
Market Cap: $5M
Sector: Healthcare
Industry: Medical - Pharmaceuticals
Exchange: NASDAQ
